Management of Pulmonary Embolism Following Cholecystectomy

Initial Assessment and Risk Stratification

The European Society of Cardiology recommends stratifying patients based on hemodynamic stability to identify those at high risk of early mortality 1, 3
The European Respiratory Society recommends performing CTPA as the initial lung imaging modality for non-massive PE 4
The European Society of Cardiology recommends assessing clinical probability using validated criteria before proceeding with diagnostic workup 2
The European Society of Cardiology recommends measuring D-dimer in patients with low or intermediate clinical probability (not in high probability cases) 2, 4

The European Society of Cardiology recommends administering systemic thrombolytic therapy as first-line treatment for high-risk PE unless contraindicated 1, 3
The European Society of Cardiology recommends considering surgical pulmonary embolectomy when thrombolysis is contraindicated or has failed 1, 2
The European Society of Cardiology recommends initiating intravenous unfractionated heparin without delay, including a weight-adjusted bolus injection 2, 3
The European Society of Cardiology recommends providing oxygen supplementation to correct hypoxemia 3
The European Society of Cardiology recommends correcting systemic hypotension to prevent progression of right ventricular failure 3

The European Society of Cardiology recommends preferring LMWH or fondaparinux over UFH for initial parenteral anticoagulation in hemodynamically stable patients 1, 2
The European Society of Cardiology recommends preferring NOACs (apixaban, dabigatran, edoxaban, or rivaroxaban) over VKAs in eligible patients 1, 2
The European Society of Cardiology recommends overlapping VKAs with parenteral anticoagulation until an INR of 2.5 (range 2.0-3.0) is reached 1, 2
The European Society of Cardiology recommends administering therapeutic anticoagulation for at least 3 months to all patients with PE 1, 2

The European Society of Cardiology recommends routinely re-evaluating patients 3-6 months after acute PE 1, 3
The European Society of Cardiology recommends implementing an integrated model of care to ensure optimal transition from hospital to ambulatory care 1, 3
The European Society of Cardiology recommends considering discontinuing anticoagulation after 3 months in patients with first PE secondary to a major transient risk factor (such as surgery) 1, 2
The European Society of Cardiology recommends continuing oral anticoagulant treatment indefinitely in patients with recurrent VTE not related to a major transient risk factor 1, 2

The European Society of Cardiology recommends not delaying anticoagulation while awaiting diagnostic confirmation in patients with intermediate or high clinical probability 2
The European Society of Cardiology recommends not measuring D-dimers in patients with high clinical probability, as a normal result does not safely exclude PE 2, 4
The European Society of Cardiology recommends not routinely administering systemic thrombolysis as primary treatment in patients with intermediate- or low-risk PE 1, 2
The European Society of Cardiology recommends not routinely using inferior vena cava filters 1, 2
The European Society of Cardiology recommends not using NOACs in patients with severe renal impairment or antiphospholipid antibody syndrome 1, 2